LivaNova (NASDAQ:LIVN) Updates FY 2024 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.300-3.400 for the period, compared to the consensus estimate of 3.160. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

LivaNova Stock Down 0.9 %

NASDAQ LIVN traded down $0.49 during trading on Friday, hitting $51.13. The stock had a trading volume of 441,625 shares, compared to its average volume of 621,637. The company has a market capitalization of $2.78 billion, a PE ratio of 122.90 and a beta of 1.00. LivaNova has a 12 month low of $42.75 and a 12 month high of $64.47. The company’s 50-day moving average price is $51.04 and its two-hundred day moving average price is $53.14. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.37.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.15. LivaNova had a net margin of 1.91% and a return on equity of 13.81%. The business had revenue of $318.60 million for the quarter, compared to analyst estimates of $305.05 million. As a group, sell-side analysts forecast that LivaNova will post 2.58 EPS for the current year.

Wall Street Analyst Weigh In

LIVN has been the topic of several analyst reports. Stifel Nicolaus boosted their price target on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Mizuho decreased their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday. Robert W. Baird upped their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, The Goldman Sachs Group started coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.